Vancomycin inhalation powder + Placebo inhalation powder + Vancomycin inhalation powder
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
MRSA
Conditions
MRSA, Cystic Fibrosis
Trial Timeline
Sep 20, 2017 → Jan 15, 2021
NCT ID
NCT03181932About Vancomycin inhalation powder + Placebo inhalation powder + Vancomycin inhalation powder
Vancomycin inhalation powder + Placebo inhalation powder + Vancomycin inhalation powder is a phase 3 stage product being developed by Savara for MRSA. The current trial status is completed. This product is registered under clinical trial identifier NCT03181932. Target conditions include MRSA, Cystic Fibrosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03181932 | Phase 3 | Completed |
Competing Products
4 competing products in MRSA
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Chlorhexidine gluconate soap + Chlorhexidine gluconate oral rinse + Mupirocin calcium 2 % ointment | Johnson & Johnson | Approved | 85 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |
| EDP-322 | Enanta Pharmaceuticals | Phase 1 | 25 |